Advancing liquid biopsies in pediatric brain tumors: unlocking the clinical utility of circulating cell-free small RNAs

Abstract Tissue specimens remain the gold standard for diagnosis and molecular characterization of cancer, but their acquisition is invasive and often difficult to repeat, particularly in pediatric neuro-oncology. Liquid biopsies offer a minimally invasive approach for obtaining tumor-related information from accessible biofluids. Blood, including plasma and serum, is the most widely investigated matrix, while cerebrospinal fluid (CSF) is biologically closer to central nervous system (CNS) tumors and may provide a higher tumor-derived signal. Molecular profiling through liquid biopsies therefore has considerable potential to support precision medicine, longitudinal disease assessment, and treatment monitoring in children with brain tumors. Among circulating regulatory RNAs, canonical small RNAs include microRNAs (miRNAs), PIWI-interacting RNAs (piRNAs), and tRNA-derived small RNAs (tsRNAs), whereas circular RNAs (circRNAs) represent a structurally and size-distinct RNA class that can also be detected in biofluids. Current pediatric clinical evidence is strongest for circulating miRNAs, with studies supporting potential diagnostic, prognostic, disease-monitoring, and treatment-response assessment applications across several pediatric CNS tumor entities. In contrast, circulating piRNAs and tsRNAs remain largely supported by adult, mixed-age, or preclinical glioma studies and require dedicated validation in pediatric cohorts. Adult-derived findings remain valuable as hypothesis-generating translational evidence when pediatric data are unavailable, but should not be considered directly transferable without independent pediatric validation. Interpretation of circulating RNA signatures also requires consideration of their biological origin. Circulating RNAs may derive directly from tumor cells, but can also reflect immune and inflammatory responses, blood-cell or platelet contributions, treatment effects, and blood–brain or blood-tumor barrier permeability. Their detection in peripheral blood therefore cannot be attributed simply to small molecular size, and circulating profiles may not faithfully reproduce the tumor RNA landscape. Clinical translation further depends on rigorous control of pre-analytical and analytical variables, including biofluid selection, hemolysis, collection and processing procedures, storage, RNA isolation, normalization, and platform choice. Although small-RNA sequencing, RT-qPCR, and digital PCR provide complementary opportunities for discovery and validation, most circulating RNA biomarkers in pediatric brain tumors remain investigational. Prospective, multicenter validation in molecularly defined pediatric cohorts, standardized workflows, demonstration of analytical and clinical performance, and independent clinical utility assessment will be essential before these biomarkers can be integrated into routine patient management.

Authors

Institutions

Publication Details

Journal
Advanced Biotechnology
Published
2026-11-13
DOI
https://doi.org/10.1007/s44307-026-00144-5
Primary Topic
Cancer Genomics and Diagnostics
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Advancing liquid biopsies in pediatric brain tumors: unlocking the clinical utility of circulating cell-free small RNAs

Claudia Vegetti, Veronica Biassoni, Loris De Cecco, Roberta Mortarini et al.
Advanced Biotechnology
Cancer Genomics and Diagnostics
article

Advancing liquid biopsies in pediatric brain tumors: unlocking the clinical utility of circulating cell-free small RNAs

Claudia Vegetti, Veronica Biassoni, Loris De Cecco, Roberta Mortarini, Elisabetta Schiavello, Olga Nigro, Maura Massimino, Matilde Oriani, Chiara Dossena, Alessandra Molla, Linda Gregorio
article en

Abstract

Abstract Tissue specimens remain the gold standard for diagnosis and molecular characterization of cancer, but their acquisition is invasive and often difficult to repeat, particularly in pediatric neuro-oncology. Liquid biopsies offer a minimally invasive approach for obtaining tumor-related information from accessible biofluids. Blood, including plasma and serum, is the most widely investigated matrix, while cerebrospinal fluid (CSF) is biologically closer to central nervous system (CNS) tumors and may provide a higher tumor-derived signal. Molecular profiling through liquid biopsies therefore has considerable potential to support precision medicine, longitudinal disease assessment, and treatment monitoring in children with brain tumors. Among circulating regulatory RNAs, canonical small RNAs include microRNAs (miRNAs), PIWI-interacting RNAs (piRNAs), and tRNA-derived small RNAs (tsRNAs), whereas circular RNAs (circRNAs) represent a structurally and size-distinct RNA class that can also be detected in biofluids. Current pediatric clinical evidence is strongest for circulating miRNAs, with studies supporting potential diagnostic, prognostic, disease-monitoring, and treatment-response assessment applications across several pediatric CNS tumor entities. In contrast, circulating piRNAs and tsRNAs remain largely supported by adult, mixed-age, or preclinical glioma studies and require dedicated validation in pediatric cohorts. Adult-derived findings remain valuable as hypothesis-generating translational evidence when pediatric data are unavailable, but should not be considered directly transferable without independent pediatric validation. Interpretation of circulating RNA signatures also requires consideration of their biological origin. Circulating RNAs may derive directly from tumor cells, but can also reflect immune and inflammatory responses, blood-cell or platelet contributions, treatment effects, and blood–brain or blood-tumor barrier permeability. Their detection in peripheral blood therefore cannot be attributed simply to small molecular size, and circulating profiles may not faithfully reproduce the tumor RNA landscape. Clinical translation further depends on rigorous control of pre-analytical and analytical variables, including biofluid selection, hemolysis, collection and processing procedures, storage, RNA isolation, normalization, and platform choice. Although small-RNA sequencing, RT-qPCR, and digital PCR provide complementary opportunities for discovery and validation, most circulating RNA biomarkers in pediatric brain tumors remain investigational. Prospective, multicenter validation in molecularly defined pediatric cohorts, standardized workflows, demonstration of analytical and clinical performance, and independent clinical utility assessment will be essential before these biomarkers can be integrated into routine patient management.

Advanced BiotechnologyVol. 4(4)
Fondazione IRCCS Istituto Nazionale dei Tumori (IT)
Cancer Genomics and Diagnostics
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon